- Home
- CSGS vs DVAX Comparison
CSGS vs DVAX Comparison
Compare CSGS & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGS
- DVAX
- Stock Information
- Founded
- CSGS 1994
- DVAX 1996
- Country
- CSGS United States
- DVAX United States
- Employees
- CSGS N/A
- DVAX N/A
- Industry
- CSGS EDP Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- CSGS Technology
- DVAX Health Care
- Exchange
- CSGS Nasdaq
- DVAX Nasdaq
- Market Cap
- CSGS 1.5B
- DVAX 1.7B
- IPO Year
- CSGS 1996
- DVAX 2004
- Fundamental
- Price
- CSGS $52.85
- DVAX $12.45
- Analyst Decision
- CSGS Buy
- DVAX Buy
- Analyst Count
- CSGS 4
- DVAX 2
- Target Price
- CSGS $62.00
- DVAX $23.00
- AVG Volume (30 Days)
- CSGS 187.7K
- DVAX 1.8M
- Earning Date
- CSGS 02-05-2025
- DVAX 02-20-2025
- Dividend Yield
- CSGS 2.27%
- DVAX N/A
- EPS Growth
- CSGS N/A
- DVAX N/A
- EPS
- CSGS 2.27
- DVAX 0.15
- Revenue
- CSGS $1,177,920,000.00
- DVAX $260,810,000.00
- Revenue This Year
- CSGS $3.48
- DVAX $21.64
- Revenue Next Year
- CSGS $2.89
- DVAX $19.81
- P/E Ratio
- CSGS $23.25
- DVAX $82.38
- Revenue Growth
- CSGS 1.39
- DVAX N/A
- 52 Week Low
- CSGS $39.56
- DVAX $9.74
- 52 Week High
- CSGS $57.16
- DVAX $14.30
- Technical
- Relative Strength Index (RSI)
- CSGS 57.39
- DVAX 41.74
- Support Level
- CSGS $49.23
- DVAX $12.27
- Resistance Level
- CSGS $51.69
- DVAX $12.74
- Average True Range (ATR)
- CSGS 1.04
- DVAX 0.35
- MACD
- CSGS 0.23
- DVAX -0.06
- Stochastic Oscillator
- CSGS 99.18
- DVAX 37.39
About CSGS CSG Systems International Inc.
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, the company generates revenue from Americas (principally the U.S.).
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.